Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05195710 · ClinicalTrials.gov registry record · Phase 1
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
A Phase 1 study of Metastases, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05195710 is a Phase 1 study of Metastases that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 130-participant average among 5 other Metastases trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05195710, a Phase 1 study of Metastases, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.
Conditions Studied
Interventions
- DRUG Yttrium-90 (Y-90) resin microspheres
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05195710
The ClinicalTrials.gov registry entry for NCT05195710 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 5 other Metastases trials with a reported enrollment target (62% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastases appearing as the primary indexed condition, and to 1 intervention - of which Yttrium-90 (Y-90) resin microspheres is the first listed.
NCT05195710 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05195710 about?
NCT05195710 is a clinical study titled "Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases". A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.
What is the current status of trial NCT05195710?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-11-16. Estimated completion is 2026-03-31.
What conditions does trial NCT05195710 study?
This clinical trial studies the following conditions: Metastases.
What interventions are being tested in trial NCT05195710?
The interventions under investigation include: Yttrium-90 (Y-90) resin microspheres (DRUG).
Who is sponsoring clinical trial NCT05195710?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05195710 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
ACTIVE NOT RECRUITING · Phase 1
-
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
COMPLETED · Phase 1
-
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
COMPLETED · Phase 2
-
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
COMPLETED · Phase 2
-
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.